<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03392909</url>
  </required_header>
  <id_info>
    <org_study_id>HS-17-00995</org_study_id>
    <nct_id>NCT03392909</nct_id>
  </id_info>
  <brief_title>Intravenous Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB)</brief_title>
  <official_title>Restoration of Full-Length Type VII Collagen in RDEB Patients With Nonsense Mutations After Intravenous Gentamicin Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recessive dystrophic epidermolysis bullosa (RDEB) is an incurable, devastating, inherited&#xD;
      skin disease caused by mutations in the COL7A1 gene that encodes for type VII collagen (C7),&#xD;
      the major component of anchoring fibrils (AFs), structures that mediate epidermal-dermal&#xD;
      adherence. Thirty percent of RDEB patients have nonsense mutations. The investigators&#xD;
      recently demonstrated in 5 such patients that intradermal and topical gentamicin induced&#xD;
      &quot;read-through&quot; of their nonsense mutations and created robust and sustained new C7 and AFs at&#xD;
      the dermal-epidermal junction (DEJ) of their skin and also stimulated wound closure and&#xD;
      reduced new blister formation. No untoward side effects occurred. Herein, the investigators&#xD;
      propose evaluating the safety and efficacy of intravenous gentamicin in these patients. In&#xD;
      theory, this intravenous administration has the possibility of treating simultaneously all of&#xD;
      the patients' skin wounds. The milestones will be increased C7 and AFs in the patients' DEJ,&#xD;
      improved EB Disease Activity Scores, and absence of gentamicin side effects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2018</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Full-length type VII collagen expression</measure>
    <time_frame>6 months</time_frame>
    <description>Increased expression of full-length type VII collagen as assessed by immunofluorescence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Generation of anchoring fibrils</measure>
    <time_frame>6 months</time_frame>
    <description>Generation of new anchoring fibrils as assessed by immuno-electron microscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absence of gentamicin side effects</measure>
    <time_frame>6 months</time_frame>
    <description>Absence of gentamicin side effects, especially the detection of any ototoxicity or nephrotoxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improved Disease Activity scores</measure>
    <time_frame>6 months</time_frame>
    <description>Improved epidermolysis bullosa Disease Activity scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improved Quality of Life score</measure>
    <time_frame>6 months</time_frame>
    <description>Improved Quality of Life score</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Recessive Dystrophic Epidermolysis Bullosa</condition>
  <arm_group>
    <arm_group_label>Intravenous Gentamicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous gentamicin (7.5 mgs/kg) daily for for either 14 days and then stopped or twice weekly for three months and then stopped.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gentamicin</intervention_name>
    <description>Short-term intravenous gentamicin therapy should have the advantage of treating all of the patient's multiple skin wounds simultaneously. Six patients (three adults and 3 children) will receive intravenous gentamicin (7.5 mgs/kg) daily for 14 days and then stopped. Three adult patients will receive intravenous gentamicin (7.5mg/kg) biweekly for three months and then stopped.</description>
    <arm_group_label>Intravenous Gentamicin</arm_group_label>
    <other_name>Gentamicin Sulfate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of signed and dated informed consent form&#xD;
&#xD;
          -  Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
          -  Male or female, aged 7 and up can participate in the 14 day IV gentamicin trial. Male&#xD;
             or female, aged 18 and up can participate in the 3 month IV gentamicin trial.&#xD;
&#xD;
          -  Been diagnosed with recessive dystrophic epidermolysis bullosa (RDEB) and with a&#xD;
             nonsense mutation in the COL7A1 gene.&#xD;
&#xD;
          -  Immunofluorescence evaluation of skin biopsies reveals absence or decreased intensity&#xD;
             of C7 expression at their DEJ (dermal epidermal junction) compared with normal human&#xD;
             skin biopsies.&#xD;
&#xD;
          -  Cultured fibroblasts from patient skin synthesize and secrete full-length, 290kDa C7&#xD;
             alpha chains in the presence of supplemented gentamicin (400 Î¼g/ml in culture).&#xD;
&#xD;
          -  Ability to sit or lie down for over 30 minutes for IV infusions. For those in the 3&#xD;
             month trial, to be willing to continue treatment at home under the supervision of&#xD;
             licensed and trained infusion nurses.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recent exposure to gentamicin within the past 6 weeks.&#xD;
&#xD;
          -  Pre-existing known auditory impairment.&#xD;
&#xD;
          -  Pre-existing known renal impairment.&#xD;
&#xD;
          -  Pre-existing known allergies to aminoglycosides or sulfate compounds.&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Current use of medications with known ototoxicity or nephrotoxicity.&#xD;
&#xD;
          -  Current enrollment in another experimental clinical trial involving systemic treatment&#xD;
             with C7 or C7 producing products for the treatment of RDEB.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David T. Woodley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor, University of Southern California</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mei Chen, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor, University of Southern California</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David T Woodley, MD</last_name>
    <phone>626-533-6028</phone>
    <email>dwoodley@usc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mei Chen, Ph.D</last_name>
    <phone>323-865-0621</phone>
    <email>chenm@usc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Woodley, MD</last_name>
      <phone>323-865-0956</phone>
      <email>dwoodley@usc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mei Chen, Ph.D</last_name>
      <phone>323-865-0621</phone>
      <email>chenm@usc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 2, 2018</study_first_submitted>
  <study_first_submitted_qc>January 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2018</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>David Woodley</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Nonsense Mutations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epidermolysis Bullosa</mesh_term>
    <mesh_term>Epidermolysis Bullosa Dystrophica</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gentamicins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

